Thyrocare Technologies

    THYROCARE
    Pharma
    ₹503.60
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹8,025 Cr

    P/E
    55.83
    Day range
    ₹502.95 – ₹519.85
    52-week range
    ₹342.55 – ₹662.00
    Volume
    2.05 L
    Open
    ₹506.00
    Prev close
    ₹506.95

    Latest results · Q2 FY27(consolidated)Revenue ₹271 Cr+25.1%Profit ₹15 Cr-68.2%Margin 5.6%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      51.02%, down 9.91 pts since 2025-12-01 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 56 / 100

    Factor percentiles

    Value33
    Quality82
    Momentum53
    Low volatility57

    Derived metrics

    Earn. yield
    1.8%
    Graham no.
    ₹92.39
    vs Graham
    -81.7%
    ROE ÷ P/B
    2.0%
    12-1 mom.
    +7.3%
    Return / vol
    0.28
    Magic Formula
    #238
    Piotroski
    5/6
    FCF yield
    2.4%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Thyrocare TechnologiesTHYROCARE₹8,025 Cr55.8314.5728.8%35.0%33.0%0.10+24.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 5h ago

    Headlines about Thyrocare Technologies from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    46.2
    Price / Book
    14.47
    ROE (FY26)
    28.8%
    ROCE (latest year)
    35%
    Dividend yield
    1.84%

    Moving averages (NSE)

    20-day
    ₹487.05
    Price above
    50-day
    ₹517.84
    Price below
    200-day
    ₹488.72
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +16.3%
    Profit 3Y CAGR
    +36.6%
    Revenue YoY (Sep 2026)
    +24.9%
    Profit YoY (Sep 2026)
    -68.8%
    Operating margin
    33.0%
    Net margin
    5.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr100 Cr200 Cr300 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-200 Cr-100 Cr0 Cr100 Cr200 Cr300 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr200 Cr400 Cr600 Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 28 Nov 2025: earlier bars are per pre-bonus share.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹10₹20₹30

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales135154157177166187193217196224240271
    Expenses103121115129124130135145138149163182
    Operating Profit323442484257587158757789
    OPM %23%22%27%27%25%30%30%33%30%34%32%33%
    Other Income33434553-155-41
    Interest111111110212
    Depreciation131311131714111222141214
    Profit before tax202334372847506335646834
    Tax %26%25%29%28%32%54%24%24%21%24%25%55%
    Net Profit151724261922384828495115
    EPS in Rs₹0.97₹1.12₹1.52₹1.68₹1.20₹1.36₹2.45₹3.02₹1.82₹2.96₹3.28₹1.00

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days33

    0 days since Mar 2021

    Inventory Days81

    +29 days since Mar 2021

    Days Payable109

    +53 days since Mar 2021

    Cash Conversion Cycle4

    -25 days since Mar 2021

    Working Capital Days19

    0 days since Mar 2021

    Strengths, risks & growth

    Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

    Strengths

    • Company has been maintaining a healthy dividend payout of 131%

    Risks

    • Stock is trading at 14.6 times its book value
    • Promoter holding has decreased over last quarter: -9.90%

    Compounded Sales Growth

    10 Years
    +13%
    5 Years
    +11%
    3 Years
    +16%
    TTM
    +22%

    Compounded Profit Growth

    10 Years
    +12%
    5 Years
    +8%
    3 Years
    +36%
    TTM
    +37%

    Stock Price CAGR

    10 Years
    +10%
    5 Years
    +5%
    3 Years
    +42%
    1 Year
    -2%

    Return on Equity

    10 Years
    +21%
    5 Years
    +20%
    3 Years
    +20%
    Last Year
    +28%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter60.93%60.92%60.92%51.02%-9.90 pp
    FII4.96%5.37%5.43%9.37%+3.94 pp
    DII20.52%21.00%20.92%25.92%+5.00 pp
    Public13.61%12.71%12.71%13.69%+0.98 pp

    Filed with NSE for Sept 2026: promoters 51.02%, public 48.98%

    Analysts & fund holdings

    100%
    100% recommend buy
    5 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E55.8 vs 45.1
    Sector P/B6.03
    Beta0.92

    Who holds the shares, quarter by quarter

    Mutual funds 22.91% (+3.05 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters51.0%
    • Foreign institutions9.4%
    • Mutual funds22.9%
    • Insurance1.9%
    • Other domestic institutions1.1%
    • Retail9.0%
    • Others4.7%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HSBC Midcap Fund3.20%1.54%-0.09 pp
    Nippon India Small Cap Fund2.92%0.31%-0.07 pp
    Aditya Birla SL ELSS Tax Saver Fund2.40%1.43%+0.11 pp
    Nippon India Pharma Fund2.19%1.93%-0.58 pp
    ICICI Pru Dividend Yield Fund1.39%1.79%-0.04 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.

    Computed

    Risk

    Volatility (1Y)
    41.1%
    Downside volatility
    39.5%
    Worst 5% of days
    4.0%
    Average of that tail
    5.8%
    Max drawdown (1Y)
    34.1%
    Below its peak
    22.4%

    Against the market

    Beta vs Nifty 50
    0.50
    Correlation
    0.17
    Relative strength (3M)
    -22.5%
    ATR (14)
    4.0%

    Return

    Return 1M
    +3.8%
    Return 3M
    -18.6%
    Return 6M
    +11.4%
    Return 1Y
    +11.4%
    vs 200-day average
    +3.0%

    Momentum

    RSI (14)
    51.5
    MACD histogram
    5.09
    Stochastic %K
    77.5
    ADX (14)
    18.2
    +DI / −DI
    21.8 / 22.7
    Money flow index
    28.5

    Participation

    Delivery (20d avg)
    49.3%
    vs its 60-day baseline
    -4.3 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    -1.0%
    52-week position
    51 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹192 Cr
    FCF yield
    2.4%
    Cash conversion
    1.31
    Accruals ratio
    -0.067
    Net debt
    ₹35 Cr
    Net debt / equity
    0.06
    EV / sales
    8.72
    Capex intensity
    2.5%
    Revenue CAGR
    27.9%
    Profit CAGR
    -20.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹977 Cr
    31 buys · ₹1.5 Cr
    8 sells · ₹978 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Rahul Guha
    Designated Person · Market Purchase
    Buy2,121₹10.4 L7 Nov 2026
    Priyanka Jagnani Jain
    Immediate Relative · Market Purchase
    Buy2,006₹9.0 L4 Nov 2026
    Brijesh Kumar
    KMP · Market Purchase
    Buy330₹1.5 L4 Nov 2026
    Docon Technologies Private Limited
    Promoter · Pledge Release
    Pledge7,94,69,696₹4916 Cr18 Aug 2026
    Docon Technologies Private Limited
    Promoter · Pledge Release
    Pledge1,75,00,000₹1089 Cr13 Aug 2026
    Docon Technologies Private Limited
    Promoter · Block Deal
    Sell1,31,68,657₹815 Cr13 Aug 2026
    Docon Technologies Private Limited
    Promoter · Market Sale
    Sell26,01,039₹163 Cr13 Aug 2026
    Mohammad Shadab Alam
    Designated Person · Market Sale
    Sell100₹59,8507 Aug 2026
    Priyanka Jagnani Jain
    Market Purchase
    Buy2,500₹8.8 L1 Apr 2026
    Geetanjali Satish Shahane
    Market Purchase
    Buy1,000₹3.6 L1 Apr 2026
    Rahul Guha
    Market Purchase
    Buy10,000₹36.6 L20 Mar 2026
    Piyush Singh
    Market Purchase
    Buy400₹1.5 L20 Mar 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹7.00

      Dividend - Rs 7 Per Share

      23 Jun 2026
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 2:1

      28 Nov 2025
      ex-date
    • dividend
      ₹7.00

      Interim Dividend - Rs 7 Per Share

      24 Oct 2025
      ex-date
    • dividend
      ₹21.00

      Dividend - Rs 21 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹18.00

      Dividend - Rs 18 Per Share

      16 Aug 2024
      ex-date
    • dividend
      ₹18.00

      Interim Dividend - Rs 18 Per Share

      20 Apr 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      25 Jul 2022
      ex-date
    • dividend
      ₹15.00

      Interim Dividend - Rs 15 Per Share

      11 May 2022
      ex-date
    • dividend
      ₹15.00

      Annual General Meeting/Dividend - Rs 15 Per Share

      17 Jun 2021
      ex-date
    • dividend
      ₹10.00

      Interim Dividend - Rs 10 Per Share

      12 Nov 2020
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5 Per Share

      21 Nov 2019
      ex-date
    • dividend
      ₹20.00

      Dividend - Rs 20 Per Share

      14 Aug 2019
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend- Rs 5 Per Share

      2 Aug 2018
      ex-date
    • dividend
      ₹5.00

      Interim Dividend Rs 5/- Per Share

      15 Feb 2018
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend - Rs 5/- Per Share

      3 Aug 2017
      ex-date
    • dividend
      ₹5.00

      Interim Dividend Rs 5/- Per Share (Purpose Revised)

      8 Feb 2017
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      1 Sept 2016
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find attached the Copies of Newspaper Publications for Notice of Postal Ballot

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Please find attached herewith Notice of Postal Ballot dated September 21, 2026

    Company Update
    Grant Of Employee Stock Options Under Thyrocare Employee Stock Option Scheme.

    Please find attached herewith Intimation relating Grant of Options under Thyrocare Employee Stock Option Scheme

    Insider Trading / SAST
    Closure of Trading Window

    Please find attached the Intimation for Closure of Trading Window

    Company Update
    Sale Of The Entire Shareholding Held By The Company In Nueclear Healthcare Limited (A Material Wholly Owned Subsidiary), Subject To The Approval Of The Shareholders Of The Company

    Please find attached Intimation Letter

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Please find attached intimation regarding Acquisition of Compulsorily Convertible Preference Shares of Trovera Healthcare Private Limited as part-consideration for the sale of Nueclear ....

    Company Update
    Outcome Of The Board Meeting Held On Monday, September 21, 2026

    Outcome of the Board meeting held on Monday, September 21, 2026

    Insider Trading / SAST
    Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2026 for Docon Technologies ....

    Insider Trading / SAST
    Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find enclosed herewith copies of Newspaper Publications published on September 04, 2026 in Business Standard (English) and Lakshadeep (Marathi)

    Insider Trading / SAST
    Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd

    Company Update
    Communication Received From API Holdings Limited Regarding Approval Of Scheme Of Amalgamation Of Docon Technologies Private Limited With API Holdings Limited

    Please find enclosed the Intimation regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited

    Others
    Disclosure under Regulation 30A of LODR

    Please find enclosed the Intimation regarding complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

    Filed with BSE (scrip 539871); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Open offer

      Thyrocare Technologies Limited

      28 Jun 2021
      Read on SEBI
    • Buyback - Public Announcement

      Thyrocare Technologies Limited - Public Announcement

      17 Sept 2018
      Read on SEBI

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Thyrocare Technologies: common questions

    Answered from the figures on this page.

    Thyrocare Technologies last traded at ₹503.60 (NSE, as of 18 Nov 2026). The last session moved it down 0.66%.

    Thyrocare Technologies is valued at about ₹8,025 crore (NSE, as of 18 Nov 2026).

    Thyrocare Technologies trades at a price-to-earnings ratio of 55.83 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Thyrocare Technologies has traded between ₹342.55 and ₹662.00 over the past 52 weeks, to 18 Nov 2026. It is currently 50% of the way up that range.

    Thyrocare Technologies (THYROCARE) is classified under Pharma on this site's screener.